Most recently, a combination therapy of metformin and DPP4 inhibitors with an immune checkpoint inhibitor (ICI) showed a significant improvement in clinical outcome without increasing the incidence of immune-related adverse events (irAEs) in NSCLC patients, thus supporting the concept of directing T cells against the tumor by two different, but synergistically acting, mechanisms (40). Here, DPP4 is linked to neoplasm.